© 1997 American Heart Association, Inc.
Articles |
7E3 Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Cross-reacts With the Leukocyte Integrin Mac-1 and Blocks Adhesion to Fibrinogen and ICAM-1
From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (D.I.S., H.X., C.R., N.K.R.); Celltech Therapeutics Ltd, Slough, UK (S.O.); and Harvard-MIT Division of Health Sciences and Technology, Cambridge, Mass (C.R.).
Correspondence to Daniel I. Simon, MD, Cardiovascular Division PBB-A3, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail disimon{at}bics.bwh.harvard.edu.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract Recent clinical trials suggest that blockade of integrins is a promising strategy for the treatment of acute coronary syndromes. Administration of 7E3 monoclonal antibody (mAb) Fab fragment (c7E3 Fab) directed against platelet integrin IIb/IIIa (
IIbß3,
CD41/CD61) reduces acute ischemic complications of coronary
angioplasty and clinical restenosis at 6 months. However, 7E3 mAb is
not selective for platelet IIb/IIIa but also cross-reacts with the
leukocyte integrin Mac-1 (Mß2, CD11b/CD18) and the vitronectin
receptor (vß3, CD51/CD61). Information regarding how this mAb may
affect other cells important in vascular repair is scant. Potential
interactions of c7E3 Fab with inflammatory (ie, monocytes and
neutrophils), vascular smooth muscle, and endothelial cells may
contribute to the in vivo actions of c7E3 Fab. In this study we
explored the binding of 7E3 to monocytic cells and the functional
effect of 7E3 and c7E3 Fab on Mac-1–mediated adhesion to fibrinogen
(FGN) and intercellular adhesion molecule-1 (ICAM-1), ligands abundant
in the injured vessel wall. Flow cytometry demonstrated that 7E3 bound
to THP-1 monocytic cells and identified a subpopulation (
10%) of
Mac-1 that was qualitatively similar to that recognized by CBRM1/5, a
mAb directed to an activation-specific neoepitope present on a subset
of Mac-1 molecules. mAb 7E3 bound to K562 cells transfected with just
the subunit (CD11b) of Mac-1 but not to nontransfected cells,
confirming a direct interaction between 7E3 and Mac-1. mAb 7E3 and c7E3
Fab blocked the adhesion of Mac-1–bearing cells to FGN (80±11% and
78±9% inhibition, respectively) and ICAM-1 (62±14% and 62±17%).
Both 7E3 and c7E3 Fab significantly inhibited (70±6% and 62±26%)
soluble FGN binding to human peripheral blood monocytes. Thus, c7E3 Fab
cross-reacts with the CD11b subunit of Mac-1 and interrupts
cell-extracellular matrix and cell-cell adhesive interactions and may
thereby influence the recruitment of circulating monocytes to sites of
vessel injury. Given the recent evidence that adherent and infiltrating
monocyte number directly correlates with the extent of neointimal
hyperplasia, inhibition of Mac-1–dependent adhesion and
IIb/IIIa-dependent function by c7E3 Fab may jointly contribute to the
regulation of vascular repair and to the sustained clinical benefits
observed with c7E3 Fab after angioplasty.
Key Words: integrins • monocytes • cellular adhesion • restenosis • monoclonal antibody
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Restenosis is the major limitation of all percutaneous coronary revascularization procedures, leading to recurrent anginal symptoms and repeat interventions in up to 40% of patients within 6 months.1 2 3 Restenosis is the arterial healing response to vascular injury, characterized pathologically by vessel elastic recoil, thrombus formation/incorporation, and neointimal hyperplasia secondary to smooth muscle cell proliferation and migration and excessive extracellular matrix production.4 5 6 7 8 Although various drugs (eg, heparin and angiotensin-converting enzyme inhibitors) have been successful in reducing neointimal thickening in animal models of restenosis,9 no agent has proved to be effective in large-scale clinical trials.10 Recently, however, the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications (EPIC) trial has demonstrated that bolus and 12-hour infusion of a murine/human chimeric 7E3 mAb fragment (c7E3 Fab) directed against the platelet integrin IIb/IIIa not only reduced acute ischemic complications of coronary angioplasty by 35%,11 an effect attributed primarily to the ability of c7E3 Fab to potently inhibit platelet aggregation by blocking platelet fibrinogen binding, but also reduced clinical restenosis—major ischemic events and the need for repeat revascularization procedures—at 6 months by 23%.12 The sustained benefit of c7E3 Fab has been attributed to its inhibitory effect on IIb/IIIa and to vessel wall "passivation," a process by which the vascular response to injury is attenuated through poorly characterized effects on cells and extracellular matrix of the vessel wall.
Receptors of the integrin family are an important class of cell
adhesion molecules that mediate cell-cell and cell–extracellular
matrix interactions that are central to inflammation, wound healing,
and hemostasis.13 Since integrins share common and ß
subunits and because there is a high degree of homology between subunit
families,14 it is not surprising that some mAbs bind to
more than one integrin. c7E3 Fab is not selective for platelet IIb/IIIa
(IIbß3, CD41/CD61) but also cross-reacts with the vitronectin
receptor (vß3, CD51/CD61),15 found on endothelial and
smooth muscle cells, and the integrin Mac-1 (Mß2,
CD11b/CD18),16 found on monocytes and neutrophils.
Mac-1, a leukocyte integrin that is mobilized from intracellular storage pools in response to a variety of agonists, including ADP, C5a, fMLP, and phorbol esters,17 18 is capable of binding heterogeneous ligands including ICAM-1,19 fibrin(ogen),20 21 22 and factor X.23 The binding of Mac-1 to ICAM-1 and fibrin(ogen) results in the adhesion of neutrophils/monocytes to the endothelium and to sites of fibrin deposition, respectively. After binding to factor X, Mac-1 coordinates the activation of factor X independent of tissue factor and factor VII, culminating in rapid fibrin formation.23 mAbs to Mac-1 interrupt the adhesive and migratory capability of leukocytes and reduce tissue injury in models of inflammation.24 25 26 27
Circulating monocytes are among the earliest cells recruited to sites of vessel injury28 29 and have the potential to interact with other vascular cells by secreting growth factors and cytokines.30 31 32 In fact, adherent and infiltrating monocyte number directly correlates with the extent of neointimal hyperplasia after deep vessel injury.33 Our demonstration in this study that 7E3 and c7E3 Fab inhibit Mac-1–mediated adhesion to FGN and ICAM-1 in vitro may provide an additional mechanism for the beneficial effects of this mAb therapy.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
ADP and the chemotactic peptide fMLP were purchased from Sigma Chemical Company. Human plasminogen-free FGN was purchased from Enzyme Research Laboratories. FGN was iodinated with Iodobeads as previously described.34 TGF-ß1 was from Collaborative Research Inc, and 1,25-(OH)2 vitamin D3 was a gift of Dr M. Uskokvic (Hoffman-LaRoche Laboratories, Nutley, NJ). LPM19c, a mAb to the
M subunit of Mac-1 (CD11b) that blocks FGN binding to
Mac-1,35 was purchased from DAKO Corp. The stimulating
CD18 mAb KIM127 was a generous gift of Dr Martyn Robinson (Celltech
Ltd, Slough, England).36 Additional Mac-1 mAbs included
TS1/18, a mAb to the common ß2 subunit (CD18) of Mac-1, and CBRM1/5,
a mAb to an activation-specific neoepitope in a subpopulation of Mac-1
molecules (kindly provided by Dr Timothy A. Springer, Harvard Medical
School, Boston, Mass).37 mAbs 7E3 and 10E5,38
murine mAbs to glycoprotein IIb and/or IIIa that block platelet FGN
binding, and c7E3 Fab,39 a Fab fragment of a human-mouse
genetic reconstruction of murine 7E3, in which mouse heavy and light
chain variable regions were linked to the constant domains of a human
IgG1 heavy chain and 
light chain, respectively, were kindly
provided by Dr Barry S. Coller (Mt Sinai Medical Center, New York, NY).
Soluble human ICAM-1/Ig, a recombinant fusion protein comprising the
extracellular domain of human ICAM-1 linked to the constant region of
human IgG1, was obtained from Chiron Corp. FITC-conjugated goat
anti-mouse IgG, F(ab')2 antibody was obtained from
Boehringer Mannheim Corp.
Cell Transfection
Erythroleukemic K562 cells (European Collection of Animal Cell
Cultures) were transfected with the M (CD11b) subunit of Mac-1 as
previously described.40 The CD11b gene was cloned by PCR
amplification from first-strand cDNA prepared from U937 cells
stimulated with 10 ng/mL phorbol myristate acetate for 48 hours. The
gene was cloned into the expression vector EE6 hCMV carrying a
G418-resistance marker for expression in K562 cells. This plasmid was
linearized by using Sal I and then 40 µg of linearized DNA
was transfected into 107 K562 cells by electroporation,
using a BioRad Gene Pulser unit. Cells and DNA were subjected to one
pulse at 250 V with a capacitance of 900 µF.
CHO cells transfected with human Mac-1 (CD11b/CD18) or the closely
related leukocyte integrin p150,95 (CD11c/CD18) were provided by Dr
Timothy A. Springer.35 Briefly, M (CD11b) or X
(CD11c) and ß2 (CD18) subunits of Mac-1 in pCDM8 were cotransfected
by electroporation with the pDCHIP plasmid, containing a CHO
dihydrofolate reductase minigene, into CHO DG44 cells. Cells were
selected with methotrexate, and a homogeneous population of positively
expressing cells was obtained by immunopanning. Expression was then
augmented by increasing the concentration of methotrexate (0.05 to
0.2 µmol/L) in culture. Both types of transfected cells, but not
the nontransfected DG44 cells, acquired the ability to bind soluble
125I-labeled FGN. Furthermore, Mac-1 and p150,95
transfectants bound equivalent amounts of 125I-FGN,
confirming equivalent expression of functional protein.
Cell Lines and Culture Conditions
The monocytic THP-1 cell line (American Type Culture Collection)
was maintained in RPMI 1640 and supplemented with 10% (vol/vol) FBS.
Unless otherwise indicated, medium containing 20 mmol/L HEPES,
2 mmol/L L-glutamine, 100 U/mL penicillin, and 100
µg/mL streptomycin was used in all cases. Differentiation of
monocytic cells (106 per milliliter), which is accompanied
by increased expression of Mac-1, was induced by treatment with 1 ng/mL
TGF-ß1 and 50 nmol/L 1,2-(OH)2 vitamin D3 for
24 hours.41 K562 cells were cultured in DMEM supplemented
with 10% FBS; CD11b K562 cells were cultured in DMEM containing G418
(1 mg/mL) and 10% FBS. Mac-1 and p150,95 CHO cells were cultured in
-MEM supplemented with 10% heat-inactivated, dialyzed FBS, 0.1
µmol/L methotrexate, and 10 µmol/L thymidine. Incubations were
performed at 37°C, 5% CO2. Peripheral blood mononuclear
cells were isolated from 10% (vol/vol) CPD-anticoagulated human blood
by Ficoll-Hypaque centrifugation42 and human monocytes
were separated from peripheral blood mononuclear cells by adherence to
human AB serum-coated plastic Petri dishes. Monocytes were maintained
in RPMI 1640 supplemented to 10% (vol/vol) with human AB serum.
Adhesion Assays
Adherent cells were assayed by a colorimetric method, as
previously described.43 44 Cytokine-primed monocytic THP-1
cells or Mac-1–transfected CHO cells were activated with ADP (10
µmol/L), fMLP (1 µmol/L), or the Mac-1–activating mAb KIM 127
(10 µg/mL). Activated cells were then added to wells precoated with
the Mac-1 ligands FGN (100 µg/mL) or ICAM-1 (10 µg/mL) and blocked
with gelatin. Cells (105 per well) were resuspended in
serum-free RPMI containing 0.5% BSA at 106 per milliliter
and were incubated in the presence or absence of the indicated mAbs
(intact 7E3, c7E3 Fab, 10E5 [anti-IIb/IIIa, non–cross-reacting with
Mac-1],45 and LPM19c [anti-CD11b]) at a concentration
of 1 to 20 µg/mL and placed in 96-well microtiter plates for 1 to 2
hours at 37°C. Plates were washed with 0.9% NaCl three times, and
adherent cells were fixed in methanol for 15 minutes, stained with
Giemsa, and adhesion-quantified by measuring absorbance at 540 nm. Data
are expressed as percent of maximum adherent responses of respective
sets of treatment.
Flow Cytometry
K562 or THP-1 cells (2.5x106 per milliliter) were
washed and resuspended in 200 µL of RPMI containing 2.5% BSA. Fc
receptors were blocked by addition of human serum at a final
concentration of 1%. The primary mAb was then added to the cell
suspension followed by incubation on ice for 30 minutes. Cells were
treated with ADP (10 µmol/L) or fMLP (1 µmol/L) for 15
minutes at 37°C before incubation with the primary mAb. After
washing, cells were resuspended in 200 µL of the same medium
containing FITC-conjugated goat anti-mouse F(ab')2
fragments and incubated for 30 minutes on ice. Flow cytometry was
performed on a Becton Dickinson FACScan (Becton Dickinson
Immunocytometry Systems). Excitation wavelength was set at 488 nm and
emission at 550 nm. Nonspecific fluorescence was determined on cells
incubated in the absence of the primary mAb.
Fibrinogen Binding Assay
The binding of soluble FGN to human peripheral blood monocytes
was investigated as previously described by Altieri and
coworkers20 with modification. 125I-labeled
FGN (1.0 µmol/L) was added to ADP-stimulated human monocytes
(105) adherent to microtiter wells for 60 minutes at
25°C. Cell-free FGN was removed by washing the adherent human
monocytes, and cell-bound FGN was determined by counting an aliquot of
the cell lysate. Specific binding was calculated by subtracting the
counts obtained in the presence of a 20-fold excess of unlabeled FGN
from total binding. The effect of mAbs was determined by preincubating
ADP-stimulated monocytes for 30 minutes before the addition of
125I-FGN.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Interaction of 7E3 With Myelomonocytic Cells
The ability of 7E3 to interact with monocytic cells was first explored by using flow cytometry. Prior reports that 7E3 cross-reacts with Mac-1 on blood monocytes have been cautiously interpreted due to concerns about potential platelet contamination. To exclude the possibility that the responses of monocytes would be influenced by platelet contamination, we have used a monocytic (THP-1) cell line and cell lines (K562 and CHO cells) transfected with human Mac-1. Integrin receptors require regulated and reversible activation, which can be induced by ligand binding and by cellular stimulation with a variety of agonists (eg, ADP, fMLP).46 47 Reporter mAbs are capable of defining this high-affinity or activated state. A small subpopulation of Mac-1, representing 10% to 20% of total Mac-1, is recognized by mAb CBRM1/5.37 CBRM1/5 is directed to an activation-specific neoepitope on Mac-1 and is capable of completely blocking Mac-1–dependent adhesion to FGN or ICAM-1. In contrast, LPM19c, a mAb to the
M subunit (CD11b) of Mac-1 that also blocks
adhesion to FGN and ICAM-1,35 recognizes total Mac-1
expressed. In accordance with the findings of Diamond and
Springer37 with neutrophils and monocytes, CBRM1/5 bound
to fMLP activated THP-1 cells at a significantly lower level than
LPM19c (mean fluorescence 49 versus 207; Fig 1A
). The
fraction of Mac-1–bearing cells displaying the activation epitope
recognized by CBRM1/5 ranged from 6% to 24% in THP-1 cells activated
with fMLP or ADP. Similar to CBRM1/5, 7E3 bound fMLP-activated THP-1
cells at a lower level than LPM19c (mean fluorescence 19 versus 207;
Fig 1A). We further examined whether CBRM1/5 and 7E3 recognize distinct
epitopes on activated THP-1 monocytic cells. Because c7E3 Fab is a
humanized fragment of 7E3 that is not recognized by the FITC-conjugated
anti-mouse antibody used in our flow cytometry experiments, we were
able to address this question using flow cytometry. c7E3 Fab failed to
block CBRM1/5 binding (data not shown), suggesting that these mAbs
recognize distinct epitopes.
|
To determine whether 7E3 bound directly to Mac-1 on monocytic cells, we
used erythroleukemic K562 cells, which do not express Mac-1 and are
capable of being stably transfected.40 7E3 bound to K562
cells transfected with the subunit (CD11b) of Mac-1 but not to
nontransfected cells, supporting a direct interaction between 7E3 and
Mac-1 (Fig 1B
).
7E3 and c7E3 Fab Antibodies Inhibit Mac-1–Mediated Adhesion to FGN
and ICAM-1
The functional relevance of 7E3's cross-reaction with Mac-1 was
investigated by exploring the effect of 7E3 or c7E3 Fab on cellular
adhesion to FGN and ICAM-1. The agonist fMLP increased adhesion of
monocytic THP-1 cells to FGN-coated wells >10-fold (Fig 2A and 2B). LPM19c, an anti-CD11b mAb that blocks FGN binding
to Mac-1,35 inhibited FGN adhesion by 82%
(P<.01), indicating that THP-1 cell adhesion is Mac-1
dependent. 7E3 and c7E3 Fab blocked adhesion to FGN by 80% and 78%
(P<.01), respectively. 10E5, an anti-IIb/IIIa mAb that does
not cross-react with Mac-1,45 had minimal effect. A dose
response for the inhibition of monocytic cell adhesion by 7E3 is
depicted (Fig 2C), indicating that the IC50 is 10
µg/mL.
|
To confirm the ability of 7E3 to inhibit Mac-1 function and establish
that inhibition by 7E3 or c7E3 Fab required Mac-1 expression, we also
investigated CHO cells transfected with human Mac-1. CHO cells, which
are devoid of Fc receptors, were selected for these experiments because
our soluble ICAM-1 preparation is a recombinant fusion protein
comprising the extracellular domain of ICAM-1 linked to the constant
region of human IgG1. Mac-1 CHO cells adhered to FGN after activation
with the KIM 127 mAb (Fig 3). Adhesion by Mac-1 CHO
cells was inhibited by LPM19c (95±2% inhibition), confirming the role
of Mac-1 in this adhesive pathway. Further evidence that Mac-1
expression is necessary to promote the adhesion of CHO cells to FGN is
supported by lack of demonstrable adhesion, under these conditions, of
nontransfected DG44 CHO cells (data not shown) and CHO cells
transfected with a distinct but closely related ß2 integrin, p150,95
(CD11c/CD18) (Fig 3). While p150,95 has been shown to mediate adhesion
of fMLP-activated neutrophils48 and phorbol
ester–activated B lymphocytes49 to FGN-coated surfaces,
we were unable to demonstrate significant adhesion of KIM
127–stimulated p150,95 CHO cells to FGN in this experimental system.
This lack of adhesion of p150,95 CHO cells may reflect
cell-type–specific differences (transfected versus nontransfected
cells) or different activation requirements in transfected cells.
|
We next tested whether 7E3 would inhibit Mac-1 binding to ICAM-1, an
adhesion molecule that facilitates the adhesion of monocytes and
neutrophils to the endothelium.19 KIM 127 stimulated
adhesion of Mac-1 CHO cells to ICAM-1 (Fig 4A and 4B).
LPM19c blocked adhesion to ICAM-1 by 86% (P<.01),
indicating that transfected CHO cell adhesion to ICAM-1 is Mac-1
dependent. 7E3 and c7E3 Fab reduced adhesion to ICAM-1 by 62% and
63%, respectively (P<.05), while 10E5 had no effect.
|
7E3 and c7E3 Fab Antibodies Inhibit Mac-1–Mediated
Soluble FGN Binding by Human Peripheral Blood Monocytes
To further evaluate the functional relevance of the interaction
between 7E3 and Mac-1, we investigated whether 7E3 and c7E3 Fab are
capable of modulating Mac-1 function in freshly isolated human
peripheral blood monocytes. ADP-stimulated human monocytes bound
soluble FGN (175 000 FGN molecules per cell). LPM19c inhibited FGN
binding to human monocytes by 93% (Table), confirming
that FGN binding to human monocytes is Mac-1 dependent. Both 7E3 and
c7E3 Fab significantly inhibited soluble FGN binding to human
peripheral blood monocytes. Lack of inhibition of FGN binding by 10E5,
an anti-IIb/IIIa mAb that blocks FGN binding to IIb/IIIa but not to
Mac-1,45 not only confirms the specificity of 7E3 but also
suggests that platelet contamination of peripheral blood monocytes is
unlikely to account for soluble FGN binding to human monocytes.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study demonstrates that c7E3 Fab or 7E3 directed against platelet IIb/IIIa also binds to Mac-1–expressing monocytic and transfected cells and thereby inhibits Mac-1–dependent adhesion to fibrin(ogen) and ICAM-1. mAbs that cross-react with multiple integrins have been described. Those reported include mAb 25E11, which cross-reacts with platelet IIb/IIIa and monocyte Mac-1,50 and mAb 24, which detects an epitope within the cation binding domain common to the
subunit of the leukocyte integrins LFA-1 (CD11a),
Mac-1 (CD11b), and p150,95 (CD11c).51 Altieri and
Edgington16 have previously shown that 7E3 cross-reacts
with monocyte Mac-1, recognizing an activation-dependent neoepitope
induced by agonists such as ADP and fMLP, which induce transients in
cytosolic Ca2+. However, reports that 7E3 cross-reacts with
Mac-1 have been cautiously interpreted owing to concerns about
potential platelet contamination.39 We have addressed this
concern by using a monocytic cell line and cells transfected with human
Mac-1. 7E3 bound to K562 cells transfected with the subunit (CD11b)
of Mac-1 but not to nontransfected cells, supporting a direct
interaction between 7E3 and Mac-1. The demonstration of 7E3 binding to
purified ligand binding or I domain of CD11b reported previously by
Zhou and colleagues52 provides additional compelling
evidence for a direct interaction between 7E3 and Mac-1. These prior
studies have explored the functional consequence of the cross-reaction
of 7E3 with Mac-1 by examining soluble ligand (ie, factor X) binding,
which was largely inhibited by 7E3 (75% to 88%).16 The
current study now shows that 7E3 blocks Mac-1–dependent adhesion to
fibrin(ogen) and ICAM-1, ligands abundant in the acutely injured vessel
wall.53 A dose response for the inhibition of monocytic
cell adhesion by 7E3 demonstrated an IC50 of 10 µg/mL
(67 nmol/L). This is in close agreement with the reported
Kd (150 nmol/L) of 7E3 for binding to
Mac-1–bearing monocytes.16 It is important to note that
7E3 apparently binds to Mac-1 with lower affinity than IIb/IIIa
(Kd, 3.4 nmol/L).38 Pharmacokinetic
data indicate that bolus infusion of c7E3 Fab in cynomolgus monkeys
resulted in a peak plasma concentration of 2.5 µg/mL (54 nmol/L,
assuming molecular weight of c7E3 Fab of 48 kD).39 Thus,
the relative importance of 7E3-mediated inhibition of IIb/IIIa versus
Mac-1 in vivo is currently unknown.
The avidity of integrins may be rapidly and reversibly altered from a
latent ("inactive") state to a high-affinity ("active")
state without changes in receptor number. Receptor activation, most
likely secondary to conformational change(s), increases ligand affinity
of ß1,54 ß2,36 and ß355
integrins. For example, agonist stimulation of platelets induces
fibrinogen binding to activated IIb/IIIa that is blocked by mAb
7E3.38 Coller and coworkers38 have
demonstrated that 7E3 recognizes an activation-dependent change in the
conformation of IIb/IIIa, because resting platelets bind 7E3 more
slowly than stimulated platelets. In the case of Mac-1, specific
agonists (eg, ADP, fMLP) stimulating mAbs (eg, KIM 127 and
185)36 56 and Mn2+57 are capable
of directly activating Mac-1 from a low- to high-affinity
ligand-binding state by inducing Ca2+ transients or by
binding to the ß2 subunit or divalent-cation domains of the M
subunit, respectively. Analagous to the interaction between 7E3 and
platelet IIb/IIIa, CBRM1/5 is directed to an activation-specific
epitope on leukocyte Mac-1 and is capable of completely blocking
Mac-1–dependent adhesion.37 Our data suggest the
possibility that 7E3 also binds to activated Mac-1. 7E3 bound to CD11b
K562 cells but not nontransfected K562 cells and identified a
subpopulation of Mac-1 by flow cytometry that is qualitatively similar
to the subpopulation identified by CBRM1/5. However, these mAbs
apparently recognize distinct activation epitopes, because c7E3 Fab, a
humanized Fab fragment of intact 7E3, failed to block CBRM1/5 binding
as assessed by flow cytometry.
The early response to vascular injury is characterized by migration of platelets and inflammatory cells, including monocytes, to the injured vessel wall.58 59 Therefore, the ability of 7E3 to inhibit not only IIb/IIIa-mediated platelet aggregation but also Mac-1–mediated monocyte adhesion may contribute to the process of vessel wall passivation observed clinically in the EPIC Trial. Among the earliest cells recruited into experimental vascular lesions induced in animals and spontaneous atherosclerosis in human arteries,28 29 monocytes serve as markers, initiators, and promoters of vascular injury. Balloon injury of the vessel wall is associated with a marked increase in the expression and secretion of monocyte chemoattractant protein-1.60 Pathological examination of human arteries and saphenous veins after angioplasty or stent placement has revealed monocytes adherent to and within vessel walls.61 There is emerging evidence implicating infiltrating monocytes in the pathogenesis of neointimal hyperplasia after mechanical arterial injury. The activation status of circulating monocytes62 and expression of Mac-163 at the time of angioplasty have been reported to predict later restenosis, and recently, Rogers and coworkers33 have demonstrated that the number of adherent and infiltrating monocytes exquisitely correlated with the extent of neointimal thickening and proliferation after arterial injury. Libby and coworkers7 have proposed a cascade model for restenosis, in which local inflammatory activation of endothelial cells, smooth muscle cells, and leukocytes occurs in a predictable sequence driven by ongoing autocrine and paracrine signals that persist after the original injury and contribute to later phases of intimal thickening. The precise mechanisms underlying the linkage between monocyte adhesion/infiltration and neointimal hyperplasia in this cascade model remain to be elucidated but may involve the elaboration of cytokines and growth factors chemotactic and mitogenic for smooth muscle cells.30 31 32
Therefore, we speculate that the cross-reaction of 7E3 or c7E3 Fab with
Mac-1 may play an additional role in inducing passivity of the vessel
wall by two mechanisms: (1) blocking the adhesion of monocytes to
ICAM-1 and fibrin(ogen) and (2) decreasing thrombus deposition at the
site of arterial injury by inhibiting the binding of factor X and its
activation to factor Xa, as previously shown by Altieri and
coworkers.23 Other platelet IIb/IIIa receptor inhibitors
under active clinical investigation (ie, lamifiban, tirofiban, and
xemlofiban) have varying degrees of specificity with the target (ie,
IIb/IIIa) and homologous (ie, vß3, Mac-1)
integrins.64 The clinical relevance of variable IIb/IIIa,
Mac-1, and vß3 blockade and its resultant effects on acute
ischemic complications and restenosis after percutaneous
transluminal coronary angiography remain to be determined.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grants HL02768 (to Dr Simon) and HL03104 87 (to Dr Rogers) and was aided by grant No. 13-526-945 from the American Heart Association, Massachusetts Affiliate, Inc (to Dr Simon). The authors thank Dr Barry Coller for providing 7E3, c7E3 Fab, and 10E5; Dr M. Uskokvic for providing 1,25-(OH)2 vitamin D3; Dr Timothy A. Springer for providing TS1/18, CBRM1/5, and transfected CHO cells; and Dr Martyn Robinson for providing KIM 127.
Received September 30, 1996; accepted December 3, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616-623. [Abstract]
2.
Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de
Feyter PJ, van de Brand M, Reiber JH, ten Katen HJ, van Es GA,
Hugenholtz PG. Incidence of restenosis after successful coronary
angioplasty—a time-related phenomenon: a quantitative angiographic
study in 342 consecutive patients at 1, 2, 3, and 4 months.
Circulation. 1988;77:361-371.
3. Kuntz RE, Gibson M, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting, and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25. [Abstract]
4. Waller BF. Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease. Cardiol Clin. 1989;7:749-770. [Medline] [Order article via Infotrieve]
5. Chesebro JA, Lam JYT, Badimon, Fuster V. Restenosis after arterial angioplasty: a hemorheologic response to injury. Am J Cardiol. 1987;60:10B-16B. [Medline] [Order article via Infotrieve]
6.
Liu MW, Roubin GS, King SB III. Restenosis
after coronary angioplasty: potential biologic determinants and the
role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
7. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
8. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284-1293. [Abstract]
9. Schwartz RS. Animal models of human coronary restenosis. In: Topol EJ, ed. Textbook of Interventional Cardiology. Philadelphia, Pa: WB Saunders; 1994:365-381.
10.
Pompa J, Califf RM, Topol EJ. Clinical trials of
restenosis after coronary angioplasty. Circulation. 1991;84:1426-1436.
11.
The EPIC Investigators. Use of a monoclonal antibody
directed against the platelet glycoprotein IIb/IIIa receptor in
high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
12. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet. 1994;343:881-886. [Medline] [Order article via Infotrieve]
13. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.[Medline] [Order article via Infotrieve]
14. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-554. [Medline] [Order article via Infotrieve]
15.
Charo IF, Fitzgerald LA, Steiner B, Rall SC Jr, Bekeart
LS, Phillips DR. Platelet glycoproteins IIb and IIIa: evidence
for a family of immunologically and structurally related glycoproteins
in mammalian cells. Proc Natl Acad Sci U S A. 1986;83:8351-8355.
16. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol. 1988;141:2656-2660. [Abstract]
17. Altieri DC, Wiltse WL, Edgington TS. Signal transduction initiated by extracellular nucleotides regulates high affinity ligand recognition of the adhesive receptor CD11b/CD18. J Immunol. 1990;145:662-670. [Abstract]
18. Hass R, Bartels H, Topley N, Hadam M, Kohler L, Goppelt-Strube M, Resch K. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. Eur J Cell Biol. 1989;48:282-293. [Medline] [Order article via Infotrieve]
19. Diamond MS, Staunton DE, Morlin SD, Springer TA. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell. 1991;65:961-971. [Medline] [Order article via Infotrieve]
20. Altieri DC, Mannucci PM, Capitano AM. Binding of fibrinogen to human monocytes. J Clin Invest. 1986;78:968-976.
21.
Altieri DC, Bader R, Mannucci PM, Edgington TS.
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an
inducible recognition specificity for fibrinogen. J Cell
Biol. 1988;107:1893-1900.
22.
Wright SD, Weitz JS, Huang AJ, Levin SM, Silverstein
SC, Leike JD. Complement receptor type three (CD11b/CD18) of
human polymorphonuclear leukocytes recognizes fibrinogen.
Proc Natl Acad Sci U S A. 1988;85:7734-7738.
23.
Altieri DC, Morrissey JH, Edgington TS. Adhesive
receptor Mac-1 coordinates the activation of factor X on stimulated
cells of monocytic and myeloid differentiation: an alternative
initiation of the coagulation cascade. Proc Natl Acad Sci
U S A. 1988;85:7462-7466.
24.
Rosen H, Gordon S. Monoclonal antibody to the
murine type 3 complement receptor inhibits adhesion of myelomonocytic
cells in vitro and inflammatory cell recruitment in vivo.
J Exp Med. 1987;166:1685-1701.
25. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlan JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorrhagic shock and resuscitation in rabbits. J Clin Invest. 1988;81:939-944.
26. Rosen H, Gordon S. The role of the type 3 complement receptor in the induced recruitment of myelomonocytic cells to inflammatory sites in the mouse. Am J Respir Cell Mol Biol. 1990;3:3-10.
27. Simpson PJ, Todd RF, Fantone JC, Mickelson JK, Griffin JD, Lucchesi BR. Reduction of experimental myocardial reperfusion injury by a monoclonal antibody (anti Mo1, anti CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988;81:624-629.
28. Duff GL, McMillan GC, Ritchie AC. The morphology of early atherosclerotic lesions of the aorta demonstrated by the surface technique in rabbits fed cholesterol. Am J Pathol. 1957;33:845-873.
29. Saphir O, Gore I. Evidence for an inflammatory basis of coronary arteriosclerosis in the young. Arch Pathol. 1950;49:418-426.
30. Leibovich SJ, Ross R. A macrophage-dependent factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol. 1976;84:501-514. [Abstract]
31. Glenn KC, Ross R. Human monocyte-derived growth factor(s) for mesenchymal cells: activation of secretion by endotoxin and concanavalin A. Cell. 1981;25:603-615. [Medline] [Order article via Infotrieve]
32. Martinet Y, Bitterman PB, Mornex J-F, Grotendorst GR, Martin GR, Crystal RG. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature. 1986;319:158-160. [Medline] [Order article via Infotrieve]
33.
Rogers C, Welt FGP, Karnovsky MJ, Edelman ER.
Monocyte recruitment and neointimal hyperplasia in rabbits: coupled
inhibitory effects of heparin. Arterioscler Thromb Vasc
Biol. 1996;16:1312-1318.
34.
Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo
J. Fibrin(ogen) is internalized and degraded via Mac-1
(CD11b/CD18): a nonplasmin fibrinolytic pathway.
Blood. 1993;82:2414-2422.
35.
Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL,
Springer TA. The I domain is a major recognition site on the
leukocyte integrin Mac-1 (CD11b/CD18) for four distinct
ligands. J Cell Biol. 1993;120:1031-1043.
36. Robinson MK, Andrew D, Rosen H, Brown D, Ortlepp S, Stephens P, Butcher EC. Antibody against the Leu-CAM b-chain (CD18) promotes both LFA-1 and CR3-dependent adhesion events. J Immunol. 1992;148:1080-1085. [Abstract]
37.
Diamond MS, Springer TA. A subpopulation of
Mac-1(CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and
fibrinogen. J Cell Biol. 1993;120:545-556.
38. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
39. Jordan RE, Wagner CL, Mascelli, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS. Preclinical development of c7E3 Fab, a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Boca Raton, Fla: CRC Press; 1995:281-305.
40. Ortlepp S, Stephens PE, Hogg N, Figdor CG, Robinson MK. Antibodies that activate b2 integrins can generate different ligand binding states. Eur J Immunol. 1995;25:637-643. [Medline] [Order article via Infotrieve]
41. Wong WSF, Simon DI, Rosoff PM, Rao NK, Chapman HA. Mechanisms of pertussis toxin–induced myelomonocytic cell adhesion: role of Mac-1 (CD11b/CD18) and the urokinase receptor (CD87). Immunology. 1996;88:90-97. [Medline] [Order article via Infotrieve]
42. Boyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest. 1968;97(suppl):77-89.
43.
Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S,
Chapman HA. Identification of the urokinase receptor as an
adhesion receptor for vitronectin. J Biol Chem. 1994;269:32380-32388.
44. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J Clin Invest. 1993;91:1541-1552.
45.
Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ,
Schmaier AH, Niewiarowski S, Colman RW. High molecular weight
kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils
and platelets. J Cell Biol. 1989;109:377-387.
46. Diamond MS, Springer TA. The dynamic regulation of integrin adhesiveness. Curr Biol. 1994;4:506-517.[Medline] [Order article via Infotrieve]
47. Du XP, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991;65:409-416. [Medline] [Order article via Infotrieve]
48.
Loike JD, Sodeik B, Cao L, Weitz JI, Detmers PA, Wright
SD, Silverstein SC. CD11 c/CD18 on neutrophils recognizes a
domain at the N terminus of the Aa chain of fibrinogen.
Proc Natl Acad Sci U S A. 1991;88:1044-1048.
49.
Postigo AA, Corbi AL, Sanchez-Madrid F, de Landazuri
MO. Regulated expression and function of CD11b/CD18 integrin on
human B lymphocytes: relation between attachment to fibrinogen and
triggering of proliferation through CD11 c/CD18. J Exp
Med. 1991;174:1313-1322.
50. De Nichilo MO, Shafren DR, Carter WM, Berndt MC, Burns GF, Boyd AW. A common epitope on platelet integrin aIIbb3 (glycoprotein IIbIIIa; CD41/CD61) and aMb2 (Mac-1; CD11b/CD18) detected by a monoclonal antibody. J Immunol. 1996;156:284-288. [Abstract]
51.
Dransfield I, Hogg N. Regulated expression of
Mg++ binding epitope on leukocyte integrin subunits.
EMBO J. 1989;8:3759-3765. [Medline]
[Order article via Infotrieve]
52.
Zhou L, Lee DHS, Plescia J, Lau CY, Altieri DC.
Differential ligand binding specificities of recombinant CD11b/CD18
integrin I-domain. J Biol Chem. 1994;269:17075-17079.
53.
Tanaka H, Sukhova GK, Swanson SJ, Clinton SK, Ganz P,
Cybulsky MI, Libby P. Sustained activation of vascular cells and
leukocytes in the rabbit aorta after balloon injury.
Circulation. 1993;88:1788-1803.
54.
Danilov YN, Juliano RL. Phorbol ester modulation
of integrin-mediated cell adhesion: a postreceptor event.
J Cell Biol. 1989;108:1925-1933.
55. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest. 1985;76:101-108.
56. Andrew D, Shock A, Ball E, Ortlepp S, Bell J, Robinson M. KIM 185, a monoclonal antibody to CD18 which induces a change in conformation of CD18 and promotes both LFA-1 and CR3-dependent adhesion. Eur J Immunol. 1993;23:2217-2222. [Medline] [Order article via Infotrieve]
57. Altieri DC. Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site(s) induces leukocyte adhesion. J Immunol. 1991;147:1891-1898. [Abstract]
58. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488-500. [Medline] [Order article via Infotrieve]
59. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1995;251:788-791.
60.
Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS,
Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic
injury and in platelet-derived growth factor–stimulated vascular
smooth muscle cells. Circ Res. 1992;70:314-325.
61. van Beusekom HMM, van der Giessen WJ, van Suylen RJ, Bos E, Bosman FT, Serruys PW. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol. 1993;21:45-54. [Abstract]
62.
Pietersma A, Kofflard M, de Wit LEA, Stinjen T, Kostner
JF, Serruys P, Sluiter W. Late lumen loss after coronary
angioplasty is associated with the activation status of circulating
phagocytes before treatment. Circulation. 1995;91:1320-1325.
63. Mickelson JK, Lakkis NM, Villarreal-Levy G, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol. 1996;28:345-353. [Abstract]
64.
Lefkovitz J, Plow EF, Topol EJ. Platelet
glycoprotein IIb/IIIa receptors in cardiovascular medicine.
N Engl J Med. 1995;332:1553-1559.
This article has been cited by other articles:
 |
|
 |
|
  R Iijima, R A Byrne, G Ndrepepa, S Braun, J Mehilli, P B Berger, A Schomig, and A Kastrati Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials Heart, January 15, 2009; 95(2): 107 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Orr, J. M. Taylor, S. Cartland, P. G. Bannon, C. Geczy, and L. Kritharides Conformational activation of CD11b without shedding of L-selectin on circulating human neutrophils J. Leukoc. Biol., November 1, 2007; 82(5): 1115 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gupta, A. Gylling, J. L. Alonso, T. Sugimori, P. Ianakiev, J.-P. Xiong, and M. Amin Arnaout The {beta}-tail domain ({beta}TD) regulates physiologic ligand binding to integrin CD11b/CD18 Blood, April 15, 2007; 109(8): 3513 - 3520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maioli, F. Bellandi, M. Leoncini, A. Toso, and R. P. Dabizzi Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1517 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Antoniucci Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A32 - A36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V K Bhatia and C Di Mario Darwin and the survival of the fittest in modern interventional cardiology Heart, August 1, 2006; 92(8): 1017 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Harokopakis, M. H. Albzreh, M. H. Martin, and G. Hajishengallis TLR2 Transmodulates Monocyte Adhesion and Transmigration via Rac1- and PI3K-Mediated Inside-Out Signaling in Response to Porphyromonas gingivalis Fimbriae. J. Immunol., June 15, 2006; 176(12): 7645 - 7656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sharma, R. Makkar, and J. Lardizabal Intracoronary Administration of Abciximab During Percutaneous Coronary Interventions: Should This Be the Routine and Preferred Approach? Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2006; 11(2): 136 - 141. [Abstract] [PDF]
|
|
|
|
|
|
W. Kim, M. H. Jeong, K. H. Kim, I. S. Sohn, Y. J. Hong, H. W. Park, J. H. Kim, Y. K. Ahn, J. G. Cho, J. C. Park, et al. The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction J. Am. Coll. Cardiol., March 7, 2006; 47(5): 933 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Touat, V. Ollivier, J. Dai, M.-G. Huisse, A. Bezeaud, U. Sebbag, T. Palombi, P. Rossignol, O. Meilhac, M.-C. Guillin, et al. Renewal of Mural Thrombus Releases Plasma Markers and Is Involved in Aortic Abdominal Aneurysm Evolution Am. J. Pathol., March 1, 2006; 168(3): 1022 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Hang, C.-P. Wang, H.-K. Yip, C.-H. Yang, G. B.-F. Guo, C.-J. Wu, and S.-M. Chen Early Administration of Intracoronary Verapamil Improves Myocardial Perfusion During Percutaneous Coronary Interventions for Acute Myocardial Infarction Chest, October 1, 2005; 128(4): 2593 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sciagra, G. Parodi, A. Pupi, A. Migliorini, R. Valenti, G. Moschi, G. M. Santoro, G. Memisha, and D. Antoniucci Gated SPECT Evaluation of Outcome After Abciximab-Supported Primary Infarct Artery Stenting for Acute Myocardial Infarction: The Scintigraphic Data of the Abciximab and Carbostent Evaluation (ACE) Randomized Trial J. Nucl. Med., May 1, 2005; 46(5): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Heinzelmann and H. Bosshart Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes J. Immunol., February 15, 2005; 174(4): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, H. Schuhlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P. P. Berger, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel Circulation, December 14, 2004; 110(24): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T Dirksen, G. Laarman, A. W.J van 't Hof, G. Guagliumi, W. A.L Tonino, L. Tavazzi, D. J.G.M Duncker, M. L Simoons, and on behalf of the PARI-MI Investigators The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty: Safety and efficacy of a novel tetrapeptide, ITF-1697 Eur. Heart J., March 1, 2004; 25(5): 392 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Chaves, A. G.M.R. Sousa, L. A. Mattos, A. Abizaid, R. Staico, F. Feres, M. Centemero, L. F. Tanajura, A. Abizaid, I. Pinto, et al. Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial Circulation, February 24, 2004; 109(7): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Vasudevan, N. H.M Lopes, P. N Seshiah, T. Wang, C. B Marsh, D. J Kereiakes, C. Dong, and P. J Goldschmidt-Clermont Mac-1 and Fas activities are concurrently required for execution of smooth muscle cell death by M-CSF-stimulated macrophages Cardiovasc Res, September 1, 2003; 59(3): 723 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wohrle, O. C. Grebe, T. Nusser, E. Al-Khayer, S. Schaible, M. Kochs, V. Hombach, and M. Hoher Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty Circulation, April 15, 2003; 107(14): 1840 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff Important Triad in Cardiovascular Medicine: Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Receptor Blockade Circulation, March 25, 2003; 107(11): 1556 - 1559. [Full Text] [PDF]
|
|
|
|
|
|
A.S Petronio, D Rovai, G Musumeci, R Baglini, C Nardi, U Limbruno, C Palagi, D Volterrani, and M Mariani Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty Eur. Heart J., January 1, 2003; 24(1): 67 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann and N. Jander How to best counteract the enemies? By ensuring adequate oxygen delivery Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G35 - G42. [Abstract] [PDF]
|
|
|
|
|
|
E. D. Aymong, M. J. Curtis, M. Youssef, M. M. Graham, L. Shewchuk, W. Leschuk, and T. J. Anderson Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting Circulation, June 25, 2002; 105(25): 2981 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Roffi, D. J. Moliterno, B. Meier, E. R. Powers, C. L. Grines, P. M. DiBattiste, H. C. Herrmann, M. Bertrand, K. E. Harris, L. A. Demopoulos, et al. Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up Circulation, June 11, 2002; 105(23): 2730 - 2736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Seshiah, D. J. Kereiakes, S. S. Vasudevan, N. Lopes, B. Y. Su, N. A. Flavahan, and P. J. Goldschmidt-Clermont Activated Monocytes Induce Smooth Muscle Cell Death: Role of Macrophage Colony-Stimulating Factor and Cell Contact Circulation, January 15, 2002; 105(2): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Baran, M. Nguyen, G. R. McKendall, C. T. Lambrew, G. Dykstra, S. T. Palmeri, R. J. Gibbons, S. Borzak, B. E. Sobel, S. G. Gourlay, et al. Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Circulation, December 4, 2001; 104(23): 2778 - 2783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Salter, C. F. Krieglstein, A. C. Issekutz, and D. N. Granger Platelets modulate ischemia/reperfusion-induced leukocyte recruitment in the mesenteric circulation Am J Physiol Gastrointest Liver Physiol, December 1, 2001; 281(6): G1432 - G1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Fintel From bench to bedside: GP IIb-IIIa inhibitors Neurology, September 1, 2001; 57(90002): S12 - 19. [Abstract] [Full Text]
|
|
|
|
|
|
A. M. Lincoff, D. J. Kereiakes, M. A. Mascelli, L. I. Deckelbaum, E. S. Barnathan, K. K. Patel, B. Frederick, M. T. Nakada, and E. J. Topol Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization Circulation, July 10, 2001; 104(2): 163 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ludemann, K.-L. Schulte, O. Hader, S. Brehme, H.-D. Volk, and W.-D. Docke Leukocyte/Endothelium Activation and Interactions During Femoral Percutaneous Transluminal Angioplasty Vascular and Endovascular Surgery, July 1, 2001; 35(4): 293 - 301. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Anderson, R. M. Califf, G. W. Stone, F.-J. Neumann, G. Montalescot, D. P. Miller, J. J. Ferguson III, J. T. Willerson, H. F. Weisman, and E. J. Topol Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2059 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Forsyth, D. A. Solovjov, T. P. Ugarova, and E. F. Plow Integrin {alpha}M{beta}2-Mediated Cell Migration to Fibrinogen and Its Recognition Peptides J. Exp. Med., May 21, 2001; 193(10): 1123 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kupatt, H. Habazettl, P. Hanusch, R. Wichels, D. Hahnel, B. F. Becker, and P. Boekstegers c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen : Implications for Myocardial Reperfusion Injury Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2226 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Thompson, M. W. Wakelin, K. Y. Larbi, A. Dewar, G. Asimakopoulos, M. A. Horton, M. T. Nakada, and S. Nourshargh Divergent Effects of Platelet-Endothelial Cell Adhesion Molecule-1 and {beta}3 Integrin Blockade on Leukocyte Transmigration In Vivo J. Immunol., July 1, 2000; 165(1): 426 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, A. Kastrati, C. Schmitt, R. Blasini, M. Hadamitzky, J. Mehilli, M. Gawaz, M. Schleef, M. Seyfarth, J. Dirschinger, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction J. Am. Coll. Cardiol., March 15, 2000; 35(4): 915 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Fredrickson, N. A. Turner, N. S. Kleiman, N. Graziadei, K. Maresh, M. A. Mascelli, M. B. Effron, and L. V. McIntire Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary Angioplasty Circulation, March 14, 2000; 101(10): 1122 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay Platelets and restenosis J. Am. Coll. Cardiol., March 1, 2000; 35(3): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Romberger, P. Heires, S. I. Rennard, and T. A. Wyatt beta -Adrenergic agonist modulation of monocyte adhesion to airway epithelial cells in vitro Am J Physiol Lung Cell Mol Physiol, January 1, 2000; 278(1): L139 - L147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects Arterioscler Thromb Vasc Biol, December 1, 1999; 19(12): 2835 - 2840. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon Overcoming thrombolytic resistance: Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1395 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, D. Zohlnhofer, L. Fakhoury, I. Ott, M. Gawaz, and A. Schomig Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1420 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Peter, M. Schwarz, C. Conradt, T. Nordt, M. Moser, W. Kubler, and C. Bode Heparin Inhibits Ligand Binding to the Leukocyte Integrin Mac-1 (CD11b/CD18) Circulation, October 5, 1999; 100(14): 1533 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Acute Platelet Inhibition With Abciximab Does Not Reduce In-Stent Restenosis (ERASER Study) Circulation, August 24, 1999; 100(8): 799 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Mickelson, M. N. Ali, N. S. Kleiman, N. M. Lakkis, T. W. Chow, B. J. Hughes, and C. W. Smith Chimeric 7e3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty J. Am. Coll. Cardiol., January 1, 1999; 33(1): 97 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann, R. Blasini, C. Schmitt, E. Alt, J. Dirschinger, M. Gawaz, A. Kastrati, and A. Schomig Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction Circulation, December 15, 1998; 98(24): 2695 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Li, P. Rieu, D. L. Griffith, D. Scott, and M. Amin Arnaout Two Functional States of the CD11b A-Domain: Correlations with Key Features of Two Mn2+-complexed Crystal Structures J. Cell Biol., December 14, 1998; 143(6): 1523 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Deitch, J. K. Williams, M. R. Adams, C. A. Fly, D. M. Herrington, R. E. Jordan, M. T. Nakada, J. A. Jakubowski, and R. L. Geary Effects of ß3-Integrin Blockade (c7E3) on the Response to Angioplasty and Intra-Arterial Stenting in Atherosclerotic Nonhuman Primates Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1730 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rogers, E. R. Edelman, and D. I. Simon A mAb to the beta 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits PNAS, August 18, 1998; 95(17): 10134 - 10139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Plescia, M. S. Conte, G. VanMeter, G. Ambrosini, and D. C. Altieri Molecular Identification of the Cross-reacting Epitope on alpha Mbeta 2 Integrin I Domain Recognized by Anti-alpha IIbbeta 3 Monoclonal Antibody 7E3 and Its Involvement in Leukocyte Adherence J. Biol. Chem., August 7, 1998; 273(32): 20372 - 20377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Mahoney, A. S. Weyrich, D. A. Dixon, T. McIntyre, S. M. Prescott, and G. A. Zimmerman Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes PNAS, August 28, 2001; 98(18): 10284 - 10289. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||